Cost effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.

Conclusions: Secondary prevention with clopidogrel is an attractive cost-effective option compared with aspirin for high risk patients with established PAD from the perspective of the national healthcare system in Chinese settings. PMID: 31999196 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31999196?dopt=Abstract

Source: Journal of Medical Economics - February 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research